Low carbohydrate diet-based intervention for obstructive sleep apnea and primary hypothyroidism in an obese Japanese man by Yoshio Tokuchi et al.
Tokuchi et al. Asia Pac Fam Med  (2016) 15:4 
DOI 10.1186/s12930-016-0029-8
CASE REPORT
Low carbohydrate diet-based 
intervention for obstructive sleep apnea 
and primary hypothyroidism in an obese 
Japanese man
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Abstract 
Background: Obesity is a major risk factor for obstructive sleep apnea (OSA), and weight loss is necessary in the 
overall management of obese patients with OSA. However, primary care physicians can provide only limited weight 
loss with lifestyle interventions, usually reducing a patient’s body weight by only 2.5 kg or less after 6–18 months.
Case presentation: A 45-year-old Japanese man was referred to our clinic owing to obesity, daytime sleepiness, 
and snoring during sleep. His weight was 130.7 kg and his body mass index (BMI) was 41.0 kg/m2. He underwent 
polysomnography, which revealed OSA with an apnea–hypopnea index of 71.2 events/h (normal, <5 events/h). His 
laboratory results were as follows: thyroid stimulating hormone, >500 μIU/mL; free triiodothyronine, 1.4 pg/mL; free 
thyroxine, <0.15 ng/dL; thyroid peroxidase antibody, 10 IU/mL; thyroglobulin antibody, >4000 IU/mL; total cholesterol 
(TC), 335 mg/dL; high-density lipoprotein cholesterol, 45 mg/dL; triglycerides (TGs), 211 mg/dL; low-density lipopro-
tein cholesterol, 248 mg/dL; fasting blood sugar, 86 mg/dL; and glycated hemoglobin (HbA1c), 6.1 %. These results 
showed that he also had primary hypothyroidism (Hashimoto’s disease). Continuous positive airway pressure (CPAP), 
levothyroxine replacement, and a low-carbohydrate diet (LCD) were initiated. CPAP use and a euthyroid condition 
induced by 175 μg/day levothyroxine allowed the patient to proactively reduce his body weight. After 18 months, the 
patient achieved a weight reduction of 32.4 kg (25 % of his initial weight) and a BMI reduction of 10.2 kg/m2, as well as 
improved laboratory results, including an HbA1c level of 5.3 %, TC level of 194 mg/dL, and TG level of 89 mg/dL.
Conclusion: An LCD may be an effective intervention for weight loss in obese Japanese patients with OSA. Further 
studies are needed to investigate the weight loss effect of an LCD compared with a conventional calorie-restricted 
diet. Hopefully, this case report will help to improve the management of obese Asian patients with OSA who typically 
consume a higher amount of carbohydrates.
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Background
Obesity is a major risk factor for obstructive sleep 
apnea (OSA) [1], and weight loss is necessary in the 
overall management of obese patients with OSA. How-
ever, primary care physicians can provide only limited 
weight loss by medical therapy alone. Previous trials, in 
which primary care physicians offered lifestyle coun-
seling, achieved a weight loss of only 2.5 kg or less after 
6–18 months [2, 3]. In addition, intensive medical ther-
apy or enhanced weight loss counseling for patients with 
obesity has been shown to achieve a mean weight loss of 
4.3–5.1 kg after 2–3 years [1, 2, 4]. In contrast, continu-
ous positive airway pressure (CPAP)—the standard treat-
ment for OSA—may actually increase the body weight of 
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patients [5]. On the other hand, hypothyroidism can be 
associated with OSA [6], and some symptoms, such as 
daytime sleepiness, fatigue, and lethargy, overlap for both 
diseases.
Here, we describe an obese Japanese man with OSA 
and primary hypothyroidism who was treated with CPAP, 
levothyroxine replacement, and a low-carbohydrate diet 
(LCD) and achieved a weight reduction of 32.4 kg (25 % 
of his initial weight) and a body mass index (BMI) reduc-
tion of 10.2 kg/m2 after 18 months.
Case presentation
In January 2014, a 45-year-old Japanese man was referred 
to our clinic owing to obesity, daytime sleepiness, and 
snoring during sleep. His Epworth Sleepiness Scale score 
was 10 points. He underwent overnight diagnostic poly-
somnography in February 2014. Upon admission, his 
height was 178.6 cm, weight was 130.7 kg, abdominal cir-
cumference was 122 cm, and BMI was 41.0 kg/m2. Physi-
cal examination showed that the thyroid gland was not 
palpable. His serum levels of creatine kinase and creati-
nine were elevated at 1581 U/L and 1.46 mg/dL, respec-
tively, while his other laboratory results were as follows: 
aspartate aminotransferase, 57 U/L; alanine aminotrans-
ferase, 49  U/L; lactate dehydrogenase, 353  U/L; total 
cholesterol (TC), 335  mg/dL; high-density lipoprotein 
cholesterol, 45  mg/dL; triglycerides (TGs), 211  mg/dL; 
low-density lipoprotein cholesterol, 248  mg/dL; fasting 
blood sugar, 86  mg/dL; glycated hemoglobin (HbA1c), 
6.1  %; thyroid-stimulating hormone (TSH),  >500  μIU/
mL; free triiodothyronine, 1.4  pg/mL; free thyrox-
ine,  <0.15  ng/dL; thyroid peroxidase antibody, 10  IU/
mL; and thyroglobulin antibody, >4000 IU/mL (Table 1). 
Blood samples were evaluated using routine methods at 
Sapporo Clinical Laboratory Inc. (Sapporo, Hokkaido, 
Japan). Based on these results, indicating hypothyroid-
ism and thyroglobulin antibody positivity, the patient was 
diagnosed with severe primary hypothyroidism (Hashi-
moto’s thyroiditis). His dyslipidemia and impaired glu-
cose tolerance were considered as secondary changes 
due to primary hypothyroidism and obesity. Because 
polysomnography showed an apnea–hypopnea index 
(AHI) of 71.2 events/h (normal, <5 events/h) and a mini-
mal SpO2 of 60  %, he also was diagnosed with severe 
OSA associated with autoimmune hypothyroidism. 
Therefore, in the beginning of March 2014, nasal CPAP 
(ICON+Auto, auto-adjusting CPAP; Fisher & Paykel 
Healthcare Limited, Auckland, New Zealand; minimal 
pressure, 4.0  cmH2O; maximal pressure, 18.0  cmH2O) 
and low-dose levothyroxine (12.5 μg/day) were initiated. 
Upon initiation of the CPAP therapy, the patient was 
informed that he would have to continue with the CPAP 
therapy unless his body weight decreased sufficiently.
In April 2014, the patient’s body weight had decreased 
to 125.2 kg, and post-CPAP polysomnography indicated 
improved OSA (AHI, 2.8 events/h; minimal SpO2, 88 %). 
A monthly follow-up visit was scheduled to check his 
body weight and adherence to CPAP. The memory stick 
of the CPAP machine showed that he used CPAP for 
Table 1 Laboratory results of blood samples on admission
Abnormal findings are italicized
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate 
aminotransferase, BUN blood urea nitrogen, CBC complete blood count, CK 
creatine kinase, Cl chloride; Cr creatinine, CRP C-reactive protein, FBS fasting 
blood sugar, fT3 free triiodothyronine, fT4 free thyroxine, γGTP gamma-glutamyl 
transferase, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein 
cholesterol, Hgb hemoglobin, K potassium, LDH lactate dehydrogenase, LDL-C 
low-density lipoprotein cholesterol, Na sodium, PLTs platelets, RBCs red blood 
cells, TB total bilirubin, TC total cholesterol, Tg thyroglobulin, TGs triglycerides, 
TP total protein, TPO thyroperoxidase, TSH thyroid-stimulating hormone, UA uric 
acid, WBCs white blood cells
CBC
 WBCs 5500 × 103/μL
 RBCs 452 × 104/μL
 Hgb 14.1 g/dL
 PLTs 25.6 × 104/μL
Glucose
 FBS 86 mg/dL
 HbA1c 6.1 %
Lipids
 TC 335 mg/dL
 HDL-C 45 mg/dL
 TGs 211 mg/dL
 LDL-C 248 mg/dL
Thyroid
 TSH >500 μIU/mL
 fT4 <0.15 ng/dL
 fT3 1.4 pg/mL
 Tg antibody >4000 IU/mL
 TPO antibody 10 IU/mL
Biochemistry
 TP 6.9 g/dL
 TB 0.8 mg/dL
 AST 57 U/L
 ALT 49 U/L
 LDH 353 U/L
 ALP 209 U/L
 γGTP 75 U/L
 CK 1581 U/L
 Cr 1.46 mg/dL
 UA 6.9 mg/dL
 BUN 11.4 mg/dL
 Na 139 mEq/L
 K 4.1 mEq/L
 Cl 98 mEq/L
 CRP 0.17 mg/dL
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an average of 6  h per night, 6  days a week, and that he 
had an AHI of approximately 2.0 events/h. In the course 
of gradually increasing the dose of levothyroxine, the 
patient reportedly felt better and had recovered from his 
fatigue and lethargy.
To address his weight loss as a priority, an LCD was 
initiated in July 2014 [7]. Yamada et al. [8] reported the 
benefits of a non-calorie-restricted LCD with the amount 
of carbohydrates limited to 70–130  g/day for Japanese 
patients with type 2 diabetes. The patient consumed 50 g 
of white rice per meal in addition to vegetables, fish, eggs, 
and meat in the morning and at noon; however, he did 
not eat rice, noodles, or other carbohydrates at night. 
In February 2015, the dose of 175  μg/day levothyroxine 
appeared to maintain a euthyroid state (TSH, 0.75 μIU/
mL), and his other laboratory results were within nor-
mal limits, including an HbA1c level of 5.3 %, TC level of 
194 mg/dL, and TG level of 89 mg/dL.
Finally, in July 2015, the patient’s body weight reached 
98.3  kg, a reduction of 32.4  kg (25  % of his initial body 
weight), while his BMI decreased from 41.0 to 30.8 kg/m2. 
Figure 1 shows changes in his body weight and TSH level 
over time. The patient felt motivated by the prospect of 
discontinuing the CPAP therapy, and was encouraged by 
the consistent weight loss at the monthly clinical visits. 
He also wanted to continue with the LCD because he did 
not find it difficult.
Discussion
The course of this patient provided two important clini-
cal suggestions. First, this obese Japanese man with OSA 
achieved a weight loss of 32.4 kg (25 % of his initial body 
weight) by medical therapy alone. Second, an LCD may 
be an effective intervention for obese Japanese patients 
with OSA.
There are three potential mechanisms for this patient’s 
successful weight loss. First, CPAP was able to control 
his sleepiness effectively. Second, his primary hypothy-
roidism was corrected to a euthyroid state with 175 μg/
day levothyroxine. Third, an LCD was initiated as die-
tary therapy. Therefore, both OSA and primary hypo-
thyroidism were treated simultaneously in this patient. 
He recovered from his fatigue and lethargy, thus ena-
bling him to reduce his body weight more proactively. In 
developed Western countries, bariatric surgery can be 
performed for weight loss in patients with obesity [1, 4]. 
Such surgeries have been shown to achieve a weight loss 
of 24.5–27.8 kg (20.6–24.5 % of initial body weight) after 
2–3 years [1, 4]. Therefore, the weight loss of this patient 
after 2  years was similar to that observed in those who 
have undergone bariatric surgery.
An LCD is an effective intervention for weight loss in 
patients with obesity [7]. Japanese individuals typically 
consume a higher amount of carbohydrates compared 
with Western populations, obtaining approximately 
60 % of their total energy intake from carbohydrates [9]. 
Therefore, an LCD may have a superior weight loss effect 
in obese Japanese patients. As far as we know, this is the 
first case in which an LCD was initiated in an obese Japa-
nese patient with OSA. An LCD was introduced in this 
case in July 2014. His weight loss from June to July was 
1.4 kg, whereas, from July to August, his weight loss was 
5.1  kg. Thus, the LCD seemed to accelerate his weight 
loss. His glucose and lipid metabolism also improved 
without diabetes or hyperlipidemia medication. In a 
previous large long-term observational study in Japan, 
a usual LCD was found to be significantly inversely 
associated with cardiovascular and total mortality [9]. 
Therefore, an LCD could allow Japanese primary care 
physicians to achieve clinically meaningful weight loss 
in their obese patients, which they might not be able to 
accomplish otherwise. However, because CPAP may 
increase the body weight of obese patients with OSA [5, 
10], additional therapy for weight loss is required. Fur-
thermore, weight loss after levothyroxine replacement for 
hypothyroidism does not always occur [11, 12]. In a pre-
vious study, levothyroxine achieved a weight loss of only 
4.3 kg (from an average of 83.7–79.4 kg) after 1 year [13]. 
Moreover, such weight loss occurred due to decrease in 
lean body mass, whereas fat mass did not decline [13]. 
This suggests that the weight loss after levothyroxine 
replacement was due to loss of excess body water associ-
ated with untreated myxedema [13]. Thus, levothyroxine 
replacement alone may not achieve an adequate weight 
loss in patients with hypothyroidism.
Conclusion
We described an obese Japanese man with OSA and 
primary hypothyroidism who achieved a weight loss 
































































































Fig. 1 Changes in the patient’s body weight and thyroid-stimulating 
hormone (TSH) level over time
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therapy alone. We further demonstrated that an LCD 
may be an effective intervention for weight loss in obese 
Japanese patients with OSA. Further studies are needed 
to investigate the weight loss effect of an LCD compared 
with a conventional calorie-restricted diet. Hopefully, 
this case report will help to improve the management of 
obese Asian patients with OSA who typically consume a 
higher amount of carbohydrates.
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